SKINKANDY LIMITED (SK1)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

SK1

SK1 - SKINKANDY LIMITED

FNArena Sector : Health & Nutrition
Year End: June
GICS Industry Group : Consumer Services
Debt/EBITDA: 1.12
Index:

0

LAST PRICE CHANGE +/- CHANGE % VOLUME

$2.80

11 Sep
2026

0.110

OPEN

$2.65

4.09%

HIGH

$2.80

119,031

LOW

$2.54

TARGET
$3.00

+0.10 change from previous day

 7.1% upside
OTHER COMPANIES IN THE SAME SECTOR
CLV . EBO . EXL . MCP . SIG .
FNARENA'S MARKET CONSENSUS FORECASTS
SK1: 1
Title FY25
Actual		 FY26
Actual		 FY27
Forecast		 FY28
Forecast
EPS (cps) xxx 0.6 11.0 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx - 92.2% 100.0% xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 24.2 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 2023202420252026
EPS Basic xxxxxxxxx0.6
DPS All xxxxxxxxx0.0
Sales/Revenue xxxxxxxxx90.5 M
Book Value Per Share xxxxxxxxx39.9
Net Operating Cash Flow xxxxxxxxx8.0 M
Net Profit Margin xxxxxxxxx0.71 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 2023202420252026
Return on Capital Employed xxxxxxxxx1.71 %
Return on Invested Capital xxxxxxxxx1.18 %
Return on Assets xxxxxxxxx0.90 %
Return on Equity xxxxxxxxx1.71 %
Return on Total Capital xxxxxxxxx23.36 %
Free Cash Flow ex dividends xxxxxxxxx-7.9 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 2023202420252026
Short-Term Debt xxxxxxxxx9 M
Long Term Debt xxxxxxxxx19 M
Total Debt xxxxxxxxx28 M
Goodwill - Gross xxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxx14 M
Price To Book Value xxxxxxxxx6.34

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 2023202420252026
Capex xxxxxxxxx7.4 M
Capex % of Sales xxxxxxxxx8.23 %
Cost of Goods Sold xxxxxxxxx60 M
Selling, General & Admin. Exp & Other xxxxxxxxx16 M
Research & Development xxxxxxxxx-
Investments - Total xxxxxxxxx-

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.5

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Ord Minnett

xx/xx/xxxx

3

xxxxxxxxx xx xxxx xxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

10/09/2026

1

Buy

$3.10

10.71%

Morgans notes FY27 sales rose on average 6.3% y/y for the consumer discretionary coverage with earnings (EBITDA) mean up 12.8%. Gross margin improved on average 30bps y/y while the EBIT margin fell -100bps mean and EPS grew 2.7% y/y on average.

Sales were in line with expectations and gross margins slightly above expectations. The analyst points out share prices were volatile on the result day with 6 out of 10 shares in retailers under coverage moving plus/minus 10% on the day with four positive.

On average FY27/FY28 earnings forecasts were down slightly by -0.5%/-1%, respectively.

SkinKandy remains a top pick in the sector with a Buy rating and a $3.10 target price.

FORECAST
Morgans forecasts a full year FY27 dividend of 0.00 cents and EPS of 11.00 cents.
Morgans forecasts a full year FY28 dividend of 0.00 cents and EPS of 14.00 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Jarden

27/08/2026

2

Overweight

$2.90

3.57%

Jarden maintains its Overweight rating for SkinKandy with its target price unchanged at $2.90 following second-half FY26 net profit after tax exceeding consensus by 12% alongside an in-line first-half FY27 year-to-date sales update.

Operational performance demonstrated progress on store rollouts, international preparations, and margin initiatives. The broker's estimates indicate that earnings projections remain largely unchanged following the trading update.

The analyst highlights that near-term trading trends and structural developments continue to support a positive outlook for the business.
Access Extra Coverage Research History >

SK1 STOCK CHART

FNArena News on SK1

1
Rudi’s View: Post-August Stock Picks & Best Buys

Sep 10 2026 - Rudi's View
2
Australian Broker Call *Extra* Edition – Aug 27, 2026

Aug 27 2026 - Daily Market Reports
3
FNArena Corporate Results Monitor – 26-08-2026

Aug 26 2026 - Australia
4
Rudi’s View: That’s The Way Markets Crumble

Aug 06 2026 - Rudi's View
5
In Brief: GQG, Caravel Minerals & SkinKandy

Jul 17 2026 - Weekly Reports

Latest Health & Nutrition News

1
Chemist Warehouse A Winner For Sigma Healthcare

Aug 31 2026 - Australia
2
The Defensive Proposition Of Sigma Healthcare

Mar 30 2026 - Australia
3
Sigma Healthcare’s Four Pillars Of Growth

Aug 29 2025 - Australia
4
Sigma Healthcare: Synergies, Margins In Focus

Jun 19 2025 - Australia
5
Sigma Healthcare Promises Higher Margins

Oct 03 2023 - Small Caps
6
Sigma’s Win Not Neccessarily Ebos’ Loss

Jun 14 2023 - Small Caps
7
Sigma Healthcare: Brokers Wary

Mar 31 2022 - Australia
8
Health & Wellness Boom On The ASX

Apr 29 2021 - Weekly Reports
9
M&A Now On Sigma Healthcare’s Agenda

Mar 24 2021 - Australia
10
McPherson’s Expands Into Herbal Health

Nov 04 2020 - Small Caps